Kiji Therapeutics is pioneering the development of engineered cell therapies utilizing induced pluripotent stem cell-derived mesenchymal stem cells (iPSC-MSCs) to address inflammatory diseases. The company focuses on enhancing the efficacy and manufacturing processes of these cells, which have historically faced challenges in consistency and effectiveness. Their innovative approach involves gene engineering of iPSC-MSCs, specifically transducing them with interleukin-10 (IL10) and CXCR4, which have shown promising preclinical results. This dual modification aims to improve immunomodulation and enhance the cells' ability to home to sites of inflammation, thereby potentially fulfilling the long-standing promise of MSC therapies.

Kiji Therapeutics collaborates with esteemed institutions such as CIBER, Fundación Jiménez Díaz, and CIEMAT, leveraging their expertise to advance their scientific foundation. The company is committed to delivering high-quality, consistent cell therapies that can effectively treat a broad range of inflammatory conditions. Their first product, KJ01, exemplifies this commitment, showcasing strong preclinical data that supports its efficacy. With a dedicated international team, Kiji Therapeutics aims to bring these innovative therapies to patients in need, marking a significant advancement in the field of regenerative medicine.

France

Kiji Therapeutic, Incorporated in France and Spain in 2023, develops transformative off-the-shelf engineered cell therapies for life-threatening diseases. Kiji-TX has a platform to gene engineer iPSC derived MSC cells for a targeted and optimized therapeutic benefit. The first asset is engineered with IL10/CXCR4 and targets several autoimmune diseases.

Kiji Therapeutics

Company Details